The currently available DKD therapies such as DPP-4 inhibitor (Gupta and Sen, 2019), SGLT-2 inhibitor (DeFronzo et al., 2021), ROCK inhibitors (Komers et al., 2011), ACEi and ARBs have been shown effective in combating DKD, but they could not completely prevent or reverse the progression of DKD (Kato and Natarajan, 2014; Wang et al., 2021). Here, DPP4 is linked to diabetic kidney disease.